Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


April 19, 2015 8:06 AM ET

Biotechnology

Company Overview of Celgene International Sarl

Company Overview

Celgene International Sarl operates as a biopharmaceutical company. It discovers, develops, and commercializes therapies to treat cancer and immune-inflammatory related diseases in the United States and internationally. The company was incorporated in 2003 and is based in Boudry, Switzerland. Celgene International Sarl operates as a subsidiary of Celgene Corporation.

Route de Perreux 1

Boudry,  2017

Switzerland

Founded in 2003

Phone:

41 32 729 85 00

Fax:

41 32 729 85 08

Key Executives for Celgene International Sarl

President of Europe, Middle East and Africa Region
Compensation as of Fiscal Year 2014.

Celgene International Sarl Key Developments

Italian Authorities Approves Celgene International Sarl's ABRAXANE, as a First-Line Treatment of Adult Patients with Metastatic Pancreatic Cancer

Celgene International Sarl announced that Italian authorities have issued a positive decision for NHS reimbursement of ABRAXANE® (paclitaxel formulated as albumin-bound nanoparticles, or nab-paclitaxel) in combination with gemcitabine, for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas, or pancreatic cancer. For the first time in this disease, the Italian Medicines Agency (AIFA) has recognised the important innovation that ABRAXANE brings as a therapeutic treatment for pancreatic cancer. The reimbursement decision has been published in the Italian Official Gazette no. 30, dated 6 February 2015, and it follows the December 2013European Commission (EC) approval of ABRAXANE for this indication. ABRAXANE has been available and reimbursed in Italy for the treatment of metastatic breast cancer since 2011. During the last few decades, little progress has been made in improving outcomes for patients diagnosed with pancreatic cancer. The mortality of pancreatic cancer is high, making it the fourth deadliest cancer for both men and women.1 Patients diagnosed with metastatic disease have a median life expectancy, after diagnosis, of approximately three to six months. There have been no new medications approved for pancreatic cancer in eight years.

European Commission Approves REVLIMID (lenalidomide) for the Treatment of Adult Patients

Celgene International Sarl a wholly owned subsidiary of Celgene Corporation announced that the European Commission (EC) has approved REVLIMID (lenalidomide) for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. The REVLIMID Marketing Authorisation has been updated to include this new indication in multiple myeloma, building upon the already approved indication of REVLIMID in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. The EC decision in newly diagnosed multiple myeloma was based on the results of two pivotal studies: MM-020 (also known as the FIRST trial) and MM-015.

Celgene Announces Positive Recommendation by Scottish Medicines Consortium for ABRAXANE

Celgene International Sarl announced that ABRAXANE® (paclitaxel formulated as albumin-bound nanoparticles; nab-paclitaxel), in combination with gemcitabine, has now received a positive recommendation for the treatment of metastatic pancreatic cancer by the Scottish Medicines Consortium (SMC) within the National Health Service Scotland.1 The decision follows the recent NHS England announcement to defer their review of ABRAXANE® for metastatic pancreatic cancer, allowing the treatment to remain on the National Cancer Drugs Fund (NCDF) list until a final decision is made. The mortality of pancreatic cancer is high, making it the fourth deadliest cancer for both men and women across the European Union. Patients diagnosed with metastatic disease have a median life expectancy, after diagnosis, of approximately two to six months. In the UK, pancreatic cancer is the fifth most common cancer killer with approximately 8,800 new cases diagnosed each year. In Scotland an estimated 770 new patients are diagnosed and over 740 die from the disease each year.

Similar Private Companies By Industry

Company Name Region
MykoGreen Biotechnology AG Europe
Athelas Ltd. Europe
Celonic AG Europe
BOWS Pharmaceuticals AG Europe
CYPA Laboratoire de cytologie et de pathologie cliniques SA Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Celgene International Sarl, please visit www.celgene.eu. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.